6th March 2013
Following the successful conclusion of a Series B funding at the end of 2012, Fertility Focus today announces a new board of directors and management team.
The Series B investment came from a number of sources including Midven’s Exceed Fund, the Capital for Enterprise Angel Co-Fund, and a number of independent angel investors including members of the Envestors network.
The investment follows hot on the heels of international publications of successful trial results and the European launch of OvuSense – a fertility monitor that accurately identifies ovulation and predicts a woman’s fertile period to help couples trying to conceive. West Midlands-based Fertility Focus is obtaining approval for the product to be used in the United States, and the investment will help complete that process and the roll-out of products around the world.
The company’s good news is tinged with sadness, as it makes public the untimely death of Dr Mohammed Aslam. Mo served as Technical Director from 2007 and was fundamental in every apsect of bringing its products to market. He brought boundless enthusiasm, good humour and wisdom to his role, and will be greatly missed as a close colleague within the company, as well as by our strategic partners and customers. Mo held a PhD in Chemistry from the University of Manchester and was a Fellow of the Royal Society of Chemistry.